Trials / Recruiting
RecruitingNCT06994143
A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
A Phase I, Open-Label Study of CLN-978 in Patients With Treatment-Refractory Rheumatoid Arthritis (RA)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Cullinan Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLN-978 | Specified dose on specified days |
Timeline
- Start date
- 2025-05-19
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
- First posted
- 2025-05-29
- Last updated
- 2025-07-04
Locations
2 sites across 2 countries: Germany, Italy
Source: ClinicalTrials.gov record NCT06994143. Inclusion in this directory is not an endorsement.